Annual General Meeting Statement

AI SummaryClose X

Sareum Holdings PLC provided an update ahead of its Annual General Meeting, highlighting progress on its lead candidate SDC-1801, which completed Phase 1 trials and demonstrated favorable safety and pharmacokinetic profiles, with Phase 2 enabling toxicology studies set to restart in Q1 2026 following the appointment of a new contract research organisation. The company also reported completing translational studies for SDC-1802, with a focus on haematological cancers, and has renegotiated significantly improved economic terms for SRA737, now receiving 63.5% of future revenues, while initiating a collaboration to discover blood-brain barrier-penetrant TYK2/JAK1 inhibitors for neuro-inflammatory indications. Sareum has engaged business development consultants to accelerate partnering discussions for SDC-1801 and SRA737, and its current activities are funded by existing cash resources.

Disclaimer*

UK 100

Latest directors dealings